Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.

被引：7
|
作者：
Jian, Zhou
Fan, Jia
Shi, Guo-Ming
Huang, Xiao-Yong
Wu, Dong
Liang, Fei
Yang, Guo-Huan
Lu, Jia-Cheng
Chen, Yi
Ge, Ning-Ling
Ji, Yuan
Hou, Y. Y.
Sun, Hui-Chuan
Qiu, Shuang-Jian
Ye, Qing-Hai
Huang, Xiao-Wu
Shi, Ying-Hong
Gao, Qiang
Yang, Xin-Rong
Wang, Xiao-Ying
机构：
[1] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
[2] Fudan Univ, ZhongShan Hosp, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Stat, Shanghai, Peoples R China
[5] Fudan Univ, Zhongshan Hosp, Dept Liver Surg, Shanghai, Peoples R China
[6] Zhongshan Hosp, Shanghai, Peoples R China
[7] Fudan Univ, Liver Canc Inst, Dept Hepat Oncol, Shanghai, Peoples R China
[8] Fudan Univ, Dept Pathol, Zhongshan Hosp, Shanghai, Peoples R China
[9] Fudan Univ, Liver Canc Inst, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4099
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
    Shi, Guo-Ming
    Huang, Xiao-Yong
    Wu, Dong
    Sun, Hui-Chuan
    Liang, Fei
    Ji, Yuan
    Chen, Yi
    Yang, Guo-Huan
    Lu, Jia-Cheng
    Meng, Xian-Long
    Wang, Xin-Ying
    Sun, Lei
    Ge, Ning-Ling
    Huang, Xiao-Wu
    Qiu, Shuang-Jian
    Yang, Xin-Rong
    Gao, Qiang
    He, Yi-Feng
    Xu, Yang
    Sun, Jian
    Ren, Zheng-Gang
    Fan, Jia
    Zhou, Jian
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [2] Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
    Guo-Ming Shi
    Xiao-Yong Huang
    Dong Wu
    Hui-Chuan Sun
    Fei Liang
    Yuan Ji
    Yi Chen
    Guo-Huan Yang
    Jia-Cheng Lu
    Xian-Long Meng
    Xin-Ying Wang
    Lei Sun
    Ning-Ling Ge
    Xiao-Wu Huang
    Shuang-Jian Qiu
    Xin-Rong Yang
    Qiang Gao
    Yi-Feng He
    Yang Xu
    Jian Sun
    Zheng-Gang Ren
    Jia Fan
    Jian Zhou
    Signal Transduction and Targeted Therapy, 8
  • [3] Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.
    Jian, Zhou
    Fan, Jia
    Shi, Guo-Ming
    Huang, Xiao-Yong
    Wu, Dong
    Yang, Guo-Huan
    Ji, Yuan
    Chen, Yi
    Liang, Fei
    Lu, Jia-Cheng
    Ge, Ning-Ling
    Sun, Hui-Chuan
    Huang, Xiao-Wu
    Qiu, Shuang-Jian
    He, Yi-Feng
    Yang, Xin-Rong
    Xu, Yang
    Gao, Qiang
    Sun, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
    Chen, Yajin
    Du, Chengyou
    Shen, Shunli
    Zhang, Wu
    Shan, Yunfeng
    Lyu, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Wang, Shutong
    Wang, Ting
    Dai, Shengjie
    Zhang, Shuhao
    Xie, Bingying
    Wu, Yinghao
    Hao, Chunyi
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2937 - 2944
  • [5] Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study
    Hao, Chunyi
    Du, Chengyou
    Peng, Baogang
    Zhang, Wu
    Shan, Yunfeng
    Lv, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Shen, Shunli
    Wang, Ting
    Dai, Shengjie
    Chen, Xiang
    Yan, Shican
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
    Shi, H.
    Zhu, H.
    Feng, Y.
    Liu, Y.
    Xing, P.
    Hu, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1132 - S1133
  • [7] Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma A Phase 2 Clinical Trial
    Edeline, Julien
    Touchefeu, Yann
    Guiu, Boris
    Farge, Olivier
    Tougeron, David
    Baumgaertner, Isabelle
    Ayav, Ahmet
    Campillo-Gimenez, Boris
    Beuzit, Luc
    Pracht, Marc
    Lievre, Astrid
    Le Sourd, Samuel
    Boudjema, Karim
    Rolland, Yan
    Boucher, Eveline
    Garin, Etienne
    JAMA ONCOLOGY, 2020, 6 (01) : 51 - 59
  • [8] Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial
    Zhou, J.
    Fan, J.
    Shi, G.
    Huang, X.
    Wu, D.
    Yang, G.
    Ge, N.
    Hou, Y.
    Sun, H.
    Huang, X.
    He, Y.
    Qiu, S.
    Yang, X.
    Xu, Y.
    Gao, Q.
    Huang, C.
    Lu, J.
    Sun, Q.
    Liang, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S262 - S263
  • [9] Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
    Xu, Li
    Chen, Jinzhang
    Liu, Chang
    Song, Xiaoling
    Zhang, Yanqiao
    Zhao, Haitao
    Yan, Sheng
    Jia, Weidong
    Wu, Zheng
    Guo, Yabing
    Yang, Jiayin
    Gong, Wei
    Ma, Yue
    Yang, Xiaobo
    Gao, Zhenzhen
    Zhang, Nu
    Zheng, Xin
    Li, Mengyu
    Su, Dan
    Chen, Minshan
    BMC MEDICINE, 2024, 22 (01)
  • [10] Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: A multicenter, single-arm, phase II trial.
    Lan, Chunyan
    Yang, Xielan
    Zhao, Jing
    Zheng, Min
    Yang, Fan
    Xie, Zhiwen
    Wu, Xiaoliu
    Yang, Hongying
    Wang, Wenyan
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345